Weblog

New Grants Available

Monday, July 27, 2009

New grants are available from the National Rosacea Society (NRS) to support research on potential causes and other key aspects of rosacea that may lead to improvements in its treatment and potential cure or prevention. Medical researchers can obtain application forms by contacting the National Rosacea Society, 800 South Northwest Highway, Suite 200, Barrington, Illinois 60010, telephone 888/662-5874, fax 847/382-5567, e-mail rosaceas@aol.com or by filling out the request form here.

The deadline for submitting applications is November 15, 2009. Grants will be issued following selection by the NRS medical advisory board.

Because the etiology of rosacea is unknown, a high priority in awarding grants will be given to studies relating to such areas as the pathogenesis, progression, mechanism of action, cell biology and potential genetic factors of rosacea. Research in such areas as epidemiology, predisposition, quality of life and relationships with environmental and lifestyle factors may also be funded.

More information on the NRS research grants program may be found in the Research Grants section.

Trigger Aids Research

Friday, July 10, 2009

The same biochemical process that causes people to flush when alarmed or embarrassed may be linked to the development of rosacea, according to findings presented by Dr. Richard Granstein, chairman of dermatology at Cornell University, during the recent Society for Investigative Dermatology annual meeting.

"By exploring the potential inflammatory pathways associated with common triggers of rosacea signs and symptoms, we hope to increase our biological understanding of what causes the disorder and how it progresses," Dr. Granstein said. "Such knowledge can then provide a basis for developing improvements in its treatment and control."

In research funded by the National Rosacea Society, Dr. Granstein and colleagues found that emotional stress, a common rosacea trigger, may activate the sympathetic nervous system with the release of adenosine triphosphate (ATP) from sympathetic nerves running throughout the skin’s blood vessels. In turn, the researchers discovered that ATP can induce a cascade of biochemical events within the body that may play a role in the inflammation of subtype 2 (papulopustular) rosacea.

"ATP may act as a messenger within the nervous system to regulate blood flow to the skin by signaling the dilation of blood vessels after exposure to various rosacea triggers, such as emotional stress," Dr. Granstein said.

He noted that flushing may ultimately be prompted by the nerves surrounding the blood vessels of the skin. These dermal vessels are associated with nerves containing substances such as the calcitonin gene-related peptide (CGRP), which dilate the vessels and thus may be associated with facial redness and the growth of the tiny blood vessels called telangiectasia, both signs of subtype 1 (erythematotelangiectatic) rosacea.

Upon investigating the potential significance of CGRP in prompting subtype 1 signs and symptoms, the researchers found that CGRP may play the opposite role in inflammation -- the bumps and pimples characteristic of subtype 2 rosacea. In recent tests, Dr. Granstein and colleagues observed that CGRP inhibits the stimulated release of certain chemokines (small proteins that recruit inflammatory cells) from the cells lining skin blood vessels (endothelial cells).

These results suggest that while the nerves containing CGRP may be linked to flushing, they may also serve to regulate inflammation by modulating chemokine production by the cells lining the blood vessels.

"Although there is still much work to be done to fully examine and define this complex process, substances that block or enhance the individual components of such pathways may ultimately lead to the effective control or prevention of rosacea," Dr. Granstein said.